Recent 24-month real-world paladin data demonstrate the ability of iluvien® to significantly reduce treatment burden in patients with diabetic macular edema

Paladin study data presented at the american society of retina specialists shows that post-iluvien, the percentage of eyes receiving one yearly treatment or less increased 3.2-fold compared to pre-iluvien

ALIM Ratings Summary

ALIM Quant Ranking